These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11833455)

  • 1. Heart protection study finds simvastatin reduces vascular risk in a wide range of high-risk patients.
    Collins R
    Am J Manag Care; 2002 Jan; Suppl():6. PubMed ID: 11833455
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients: why is someone still using the phase I diet for patients at risk for atherosclerosis?
    Banks T
    Am J Cardiol; 1999 Mar; 83(5):818. PubMed ID: 10080453
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cholesterol goals are now easier to reach. Half LDL cholesterol with only one tablet daily].
    MMW Fortschr Med; 2005 Nov; 147(45):55. PubMed ID: 16320656
    [No Abstract]   [Full Text] [Related]  

  • 4. [For coronary disease patients is certain: the lower the LDL the better].
    MMW Fortschr Med; 2006 Jun; 148(24):6. PubMed ID: 16850797
    [No Abstract]   [Full Text] [Related]  

  • 5. Simvastatin + ezetimibe: a combination with no proven advantages.
    Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17460829
    [No Abstract]   [Full Text] [Related]  

  • 6. [What has changed in therapy of vascular patients (role of statins and beta-adrenoblockers)].
    Pokrovskiĭ AV; Goloviuk AL
    Angiol Sosud Khir; 2010; 16(2):7-11. PubMed ID: 21032867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Journal Watch: evidence that Atorvastatin reduces the risk of stroke and myocardial infarction in patients with type 2 diabetes, but with no evidence of dyslipidaemia.
    Gangaidzo IT
    Cent Afr J Med; 2005; 51(11-12):125-6. PubMed ID: 17447346
    [No Abstract]   [Full Text] [Related]  

  • 8. Updated guidelines support even lower cholesterol levels for at-risk patients.
    Levenson D
    Rep Med Guidel Outcomes Res; 2004 Aug; 15(15):1, 6-7. PubMed ID: 15320342
    [No Abstract]   [Full Text] [Related]  

  • 9. [SBU should investigate what is an evidence-based and cost-effective use of statins].
    Hjemdahl P; Allhammar A; Heaton C; Hulting J; Kahan T; Malmström R; Martinsson A; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B
    Lakartidningen; 2009 Aug 5-18; 106(32-33):1992-4. PubMed ID: 19764381
    [No Abstract]   [Full Text] [Related]  

  • 10. Rosuvastatin for cardiovascular prevention: too many uncertainties.
    Prescrire Int; 2009 Aug; 18(102):176. PubMed ID: 19746571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Statin treatment in type 2 diabetes. Is it a must today?].
    Faust M
    MMW Fortschr Med; 2003 Feb; 145(9):35-6. PubMed ID: 12666527
    [No Abstract]   [Full Text] [Related]  

  • 12. Ezetimibe plus simvastatin cardiovascular outcomes study program.
    Padial LR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):17-25. PubMed ID: 18095904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
    Robinson JG; Davidson MH
    Expert Rev Cardiovasc Ther; 2006 Jul; 4(4):461-76. PubMed ID: 16918265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of high-dose atorvastatin therapy.
    Waters DD
    Am J Cardiol; 2005 Sep; 96(5A):69F-75F. PubMed ID: 16126026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins in threatened stroke.
    Kaste M
    Stroke; 2003 Feb; 34(2):351-3. PubMed ID: 12574533
    [No Abstract]   [Full Text] [Related]  

  • 16. [Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
    Sudhop T; von Bergmann K
    MMW Fortschr Med; 2003 May; 145(21):19. PubMed ID: 12845862
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical experience with ezetimibe/simvastatin in a Mediterranean population.
    Migdalis I; Efthimiadis A; Pappas S; Alexopoulos D; Vlasserou F; Mikhailidis DP
    Curr Med Res Opin; 2009 Oct; 25(10):2571-6. PubMed ID: 19739939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
    Tikkanen MJ; Holme I; Cater NB; Szarek M; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
    Am J Cardiol; 2009 Mar; 103(5):577-82. PubMed ID: 19231315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Despite coronary intervention, the risk remains high: PCI patients need additional protection].
    MMW Fortschr Med; 2004 Jun; 146(24):3. PubMed ID: 15366508
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.